BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting the RAGE-LCP2 interaction for sepsis

...R. Billiar, University of Pittsburgh School of Medicine, Pittsburgh, Pa.email: billiartr@upmc.eduCONTACT: Yong Jiang, Southern Medical University, Guangzhou, Chinaemail: jiang48231@163.com Claire Quang Southern Medical University University of Pittsburgh Receptor...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...stroke —a cell-penetrating peptide from a University of Pittsburgh...
...Jude Children's Research Hospital Sun Yat-sen University University of Queensland University of Pittsburgh Heidelberg...
BioCentury | Oct 28, 2020
Distillery Therapeutics

LIMS1 identified as NSCLC target

...and Technology, Shenzhen, Chinaemail: guol@sustc.edu.cnCONTACT: Chuanyue Wu, University of Pittsburgh School of Medicine, Pittsburgh, Pa.email: carywu@pitt.edu Claire Quang Southern University of Science and Technology University of Pittsburgh LIM...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...of the department of ophthalmology at the University of Pittsburgh...
...Léveillard, Florence AlloucheUniversity collaborators: Institut de la Vision, University of Pittsburgh...
BioCentury | Sep 10, 2020
Product Development

U.S. needs master protocols such as U.K.’s RECOVERY to speed COVID-19 evidence collection, McClellan says: a BioCentury audio interview

...REMAP-CAP trial network run out of UPMC [University of Pittsburgh...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Potassium channel-vesicle interaction as a target in ischemic stroke

...July 1, 2020doi: 10.1126/sciadv.aaz8110CONTACT: Jason A. Justice, University of Pittsburgh...
...Elias Aizenman, same affiliation as aboveemail: redox@pitt.edu Claire Quang University of Pittsburgh Potassium...
BioCentury | Jul 21, 2020
Emerging Company Profile

Hybrid CDMO-gene therapy developer Forge launches with $40M

...motor and sensory skills over time. FBX-101 originated in the lab of Maria Escolar, a University of Pittsburgh...
...to deliver genetic material designed to correct mutations in the GALC gene Origin of technology: University of Pittsburgh...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

...in Science Immunology suggests LAG3 expression could be a marker for responsiveness to anti-PD-1 treatment. University of Pittsburgh...
...Programmed cell death 1 RET - Ret proto-oncogene Danielle Golovin, Staff Writer Fate Therapeutics Inc. Baylor College of Medicine University of Pittsburgh Stanford...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials: Guest Commentary

...setting. One exception is the randomized, embedded, multi-factorial, adaptive platform (REMAP) trial, led by the University of Pittsburgh...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...clinical development. Lotze was vice chair of research in the department of surgery at the University of Pittsburgh...
Items per page:
1 - 10 of 323
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting the RAGE-LCP2 interaction for sepsis

...R. Billiar, University of Pittsburgh School of Medicine, Pittsburgh, Pa.email: billiartr@upmc.eduCONTACT: Yong Jiang, Southern Medical University, Guangzhou, Chinaemail: jiang48231@163.com Claire Quang Southern Medical University University of Pittsburgh Receptor...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...stroke —a cell-penetrating peptide from a University of Pittsburgh...
...Jude Children's Research Hospital Sun Yat-sen University University of Queensland University of Pittsburgh Heidelberg...
BioCentury | Oct 28, 2020
Distillery Therapeutics

LIMS1 identified as NSCLC target

...and Technology, Shenzhen, Chinaemail: guol@sustc.edu.cnCONTACT: Chuanyue Wu, University of Pittsburgh School of Medicine, Pittsburgh, Pa.email: carywu@pitt.edu Claire Quang Southern University of Science and Technology University of Pittsburgh LIM...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

...of the department of ophthalmology at the University of Pittsburgh...
...Léveillard, Florence AlloucheUniversity collaborators: Institut de la Vision, University of Pittsburgh...
BioCentury | Sep 10, 2020
Product Development

U.S. needs master protocols such as U.K.’s RECOVERY to speed COVID-19 evidence collection, McClellan says: a BioCentury audio interview

...REMAP-CAP trial network run out of UPMC [University of Pittsburgh...
BioCentury | Aug 28, 2020
Distillery Therapeutics

Potassium channel-vesicle interaction as a target in ischemic stroke

...July 1, 2020doi: 10.1126/sciadv.aaz8110CONTACT: Jason A. Justice, University of Pittsburgh...
...Elias Aizenman, same affiliation as aboveemail: redox@pitt.edu Claire Quang University of Pittsburgh Potassium...
BioCentury | Jul 21, 2020
Emerging Company Profile

Hybrid CDMO-gene therapy developer Forge launches with $40M

...motor and sensory skills over time. FBX-101 originated in the lab of Maria Escolar, a University of Pittsburgh...
...to deliver genetic material designed to correct mutations in the GALC gene Origin of technology: University of Pittsburgh...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

...in Science Immunology suggests LAG3 expression could be a marker for responsiveness to anti-PD-1 treatment. University of Pittsburgh...
...Programmed cell death 1 RET - Ret proto-oncogene Danielle Golovin, Staff Writer Fate Therapeutics Inc. Baylor College of Medicine University of Pittsburgh Stanford...
BioCentury | Jun 26, 2020
Product Development

21st century pandemic, prehistoric clinical trials: Guest Commentary

...setting. One exception is the randomized, embedded, multi-factorial, adaptive platform (REMAP) trial, led by the University of Pittsburgh...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...clinical development. Lotze was vice chair of research in the department of surgery at the University of Pittsburgh...
Items per page:
1 - 10 of 323